Business Model & Revenue
Moolec operates a molecular farming platform: engineering staple crops to express high-value proteins and specialty lipids at agricultural scale using standard farming and crushing infrastructure. Revenue comes from bulk ingredient sales to CPG, supplement, pet food, and aquaculture companies.
GLASO (GLA Safflower Oil): Engineered safflower expressing ≈45% gamma-linolenic acid (GLA) — a specialty omega-6 fatty acid commanding $15-$40/lb in supplement and cosmetic markets. The 2025 campaign (1,100 acres, +57% yield) is the first validated commercial-scale production. An unnamed CPG offtake agreement is in place; revenues not yet disclosed.
Piggy Sooy: Soybeans engineered to express pork proteins. USDA-APHIS clearance obtained. Targeting pet food and human food markets; FDA novel food designation pending.
Valorasoy: Soy-derived animal protein for aquaculture and pet food — nearest-term revenue contributor pre-GLASO commercialization. Standalone MLEC revenue ≈$6M/yr.
Post-Bioceres combination (June 2025): parent entity contributes $500M+ in legacy agtech revenue across 50+ countries, 800+ patents — none of which flows through MLEC standalone P&L.
Financial Highlights
Full-Year Results (FY2024, Standalone Pre-Merger)
| Metric | FY2024 | FY2023 | YoY% |
|---|---|---|---|
| Revenue | ≈$6.0M | ≈$5.2M | ~+15% |
| Gross Profit | ≈$1.2M | ≈$1.0M | ~+20% |
| Gross Margin | ≈20% | ≈19% | +1pp |
| Net Loss | ~($10.4M) | ~($8.8M) | N/M |
| Cash Burn | ≈$10.4M/yr | ≈$9.6M/yr | +8% |
| EPS (post-split adj.) | ~($14.32) | ~($12.12) | N/M |
Balance Sheet Snapshot (Dec 2025 Est.)
| Item | Value |
|---|---|
| Shares Outstanding | ≈726,118 |
| Market Cap | ≈$7M |
| Stockholders' Equity | Below $2.5M Nasdaq threshold |
| Nasdaq Compliance Deadline | June 29, 2026 |
| 52-Week Range (post-split adj.) | $3.08 – $157.05 |
| Reverse Split | 15-for-1 (January 5, 2026) |
GLASO 2025 Campaign Economics
| Metric | Value |
|---|---|
| Acreage | ≈1,100 acres |
| Yield | ≈2,200 lbs/acre (+57% YoY) |
| Total Safflower Harvested | ≈2.42M lbs |
| Estimated Oil Volume | ≈800K–965K lbs |
| GLA Concentration | ≈45% |
| GLA Equivalent | ≈360K–435K lbs |
| Potential Gross Revenue | $3M–$6M at specialty pricing |
Combined Entity vs. Standalone (Post-Bioceres, 2025)
| Entity | Revenue | Patents | Countries |
|---|---|---|---|
| MLEC Standalone (Valorasoy) | ≈$6M | — | — |
| Combined Post-Bioceres | $500M+ | 800+ | 50+ |
| MLEC Platform Contribution | Minimal | Core IP | U.S. focus |
Combined audited financials not yet available. Platform revenue remains ≈$6M; legacy Bioceres agtech drives the $500M+ figure.
Competitive Landscape
Moolec occupies a unique niche in alternative protein: molecular farming via field-grown crops, not bioreactors or extruded plant proteins. There are no direct public-company comps for its specific approach.
- Borage/Evening Primrose Farmers (private): Traditional GLA sources at 8-25% concentration vs. GLASO's 45%. Labor-intensive, geographically constrained, no synthetic biology advantage.
- Perfect Day (private): Precision fermentation for animal proteins (whey). Better-capitalized, more advanced commercialization — but bioreactor economics, not field-scale.
- Remilk (private): Precision fermentation for milk proteins. Same limitation: reactor-based, not agricultural-scale.
- Nature's Fynd (private): Fungi-based protein. Different biology, different supply chain.
- Beyond Meat (BYND): Plant-based meat via extrusion. No molecular farming, different market positioning, publicly comparable only on alt-protein category.
Moats:
- GLASO's 45% GLA from a commodity-infrastructure crop — no public competitor at this concentration level
- USDA-APHIS clearance for Piggy Sooy — first-mover regulatory advantage for field-expressed pork protein
- Bioceres-derived global distribution (50+ countries, 550 registrations, Agrality and Synbio Powerlabs infrastructure)
- Patent estate (800+) covering molecular farming methods and constructs
Catalysts
- Nasdaq compliance (by June 29, 2026) — securing stockholders' equity above $2.5M removes the primary binary risk and is the single biggest re-rating catalyst
- First GLASO revenue disclosure (H1 2026) — unnamed CPG/pet food offtake agreement converting to invoiced sales validates commercial demand
- 2026 GLASO acreage expansion — scaling beyond 1,100 acres with validated 45% GLA demonstrates repeatability and margin improvement potential
- Piggy Sooy FDA consultation progress — advancing novel food designation clears the path to U.S. food-grade market
- Combined entity audited financials — transparency on post-Bioceres balance sheet and synergies removes a key investor uncertainty overhang
Key Risks
- Nasdaq delisting (June 29, 2026): Failed $2.5M equity requirement — conditional exception expires in four months; delisting is a binary wipeout risk for shareholders
- Going concern and dilution: Bioceres parent-entity debt restricts financing access; any capital raise at a $7M market cap is massively dilutive to existing holders
- Extreme illiquidity: ≈726K shares outstanding, $7M market cap — trivially manipulated, massive bid-ask spreads, 52-week range $3.08–$157.05
- No disclosed GLASO revenue: Offtake agreement has no published terms, volumes, or pricing — commercial conversion from scientific milestone to revenue is entirely unproven
- FDA pathway for Piggy Sooy is multi-year and uncertain — USDA-APHIS agricultural clearance does not imply food-grade approval on any predictable timeline
Our Thesis
Moolec's molecular farming platform — engineering crops to grow animal proteins and specialty lipids at field scale using standard agricultural infrastructure — is arguably the most differentiated idea in alternative protein. GLASO's validated ≈45% GLA concentration from U.S. safflower is a genuine milestone no competitor has matched; borage offers 20-25%, evening primrose 8-10%. The June 2025 Bioceres combination (800+ patents, 550 registrations, 50+ countries, $500M+ revenue) transformed a $7M nano cap into something with real commercial infrastructure. CEO Antalich (ex-Nutrecon, ≈$300M exit) brings execution credibility. Piggy Sooy — the world's only field-scale pork protein expressed in soybeans — holds USDA-APHIS clearance and is advancing toward FDA.
We don't buy distressed shells trading on science alone. The going concern disclosure reflects real financing constraints: Bioceres parent-entity debt restricts capital access and any raise at this market cap is massively dilutive. Nasdaq delisting in four months is a binary wipeout risk, not a footnote. The $9.00 price target is a show-me placeholder — not a conviction call. Three upgrade triggers: (1) Nasdaq equity compliance secured, (2) first disclosed GLASO revenue from the unnamed CPG offtake agreement, (3) going concern language lifted. All three together justify Speculative Buy at $20-25+. Until then: Neutral. Find alpha where nobody's looking — but not here, not yet.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.